Incidences of Secondary Malignancies After Androgen Deprivation Therapy for Prostate Cancer

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2025-05-20 DOI:10.1016/j.clgc.2025.102379

Junghoon Lee , Min Chul Cho , Hyeon Jeong , Hwancheol Son , Sangjun Yoo

{"title":"Incidences of Secondary Malignancies After Androgen Deprivation Therapy for Prostate Cancer","authors":"Junghoon Lee , Min Chul Cho , Hyeon Jeong , Hwancheol Son , Sangjun Yoo","doi":"10.1016/j.clgc.2025.102379","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>We aimed to assess the effects of ADT on the incidence of secondary malignancies in patients with prostate cancer.</div></div><div><h3>Methods</h3><div>Prostate cancer patients who initially treated with ADT from 2009 were included and followed up until 2019. We additionally included female patients, male patients without prostate cancer, and male patients with prostate cancer who did not undergo ADT to build comparison. A 1:1:1:1 match based on age was performed, and 55,865 individuals from each group were selected for analysis.</div></div><div><h3>Results</h3><div>The incidence of common cancers was compared between the groups. All cancers, except thyroid and breast cancers, were more common in men than women. All cancers were more common in men with prostate cancer than in men without prostate cancer, regardless of ADT. After ADT, the incidences of thyroid and breast cancers increased, whereas the incidences of liver and pancreatic cancers decreased. In the multivariate analysis, all types of cancer were more common in men with prostate cancer than in men without prostate cancer, regardless of ADT. Among these, the incidence of liver and pancreatic cancers significantly decreased after ADT.</div></div><div><h3>Conclusion</h3><div>The incidence of several secondary malignancies was affected not only by sex but also by prostate cancer diagnosis and ADT. Although further studies are required, these data could be important for health checkups and the management of prostate cancer survivors, especially prostate cancer patients who have been treated with ADT.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102379"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767325000795","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

We aimed to assess the effects of ADT on the incidence of secondary malignancies in patients with prostate cancer.

Methods

Prostate cancer patients who initially treated with ADT from 2009 were included and followed up until 2019. We additionally included female patients, male patients without prostate cancer, and male patients with prostate cancer who did not undergo ADT to build comparison. A 1:1:1:1 match based on age was performed, and 55,865 individuals from each group were selected for analysis.

Results

The incidence of common cancers was compared between the groups. All cancers, except thyroid and breast cancers, were more common in men than women. All cancers were more common in men with prostate cancer than in men without prostate cancer, regardless of ADT. After ADT, the incidences of thyroid and breast cancers increased, whereas the incidences of liver and pancreatic cancers decreased. In the multivariate analysis, all types of cancer were more common in men with prostate cancer than in men without prostate cancer, regardless of ADT. Among these, the incidence of liver and pancreatic cancers significantly decreased after ADT.

Conclusion

The incidence of several secondary malignancies was affected not only by sex but also by prostate cancer diagnosis and ADT. Although further studies are required, these data could be important for health checkups and the management of prostate cancer survivors, especially prostate cancer patients who have been treated with ADT.

查看原文本刊更多论文

前列腺癌雄激素剥夺治疗后继发恶性肿瘤的发生率。

目的：我们旨在评估ADT对前列腺癌患者继发恶性肿瘤发生率的影响。方法：纳入2009年开始接受ADT治疗的前列腺癌患者，随访至2019年。我们还纳入了女性患者、未患前列腺癌的男性患者和未接受ADT治疗的男性前列腺癌患者来进行比较。根据年龄进行1:1:1:1匹配，每组抽取55,865人进行分析。结果：比较两组患者常见肿瘤的发生率。除甲状腺癌和乳腺癌外，所有癌症在男性中的发病率都高于女性。无论ADT如何，所有癌症在前列腺癌患者中都比没有前列腺癌的男性更常见。ADT后，甲状腺癌和乳腺癌的发病率上升，而肝癌和胰腺癌的发病率下降。在多变量分析中，无论ADT如何，所有类型的癌症在前列腺癌男性中都比在非前列腺癌男性中更常见。其中，ADT后肝癌和胰腺癌的发病率明显降低。结论：几种继发性恶性肿瘤的发病率不仅受性别影响，还受前列腺癌诊断和ADT的影响。虽然还需要进一步的研究，但这些数据可能对前列腺癌幸存者的健康检查和管理很重要，尤其是接受过ADT治疗的前列腺癌患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.